Dual-target inhibitors of colchicine binding site for cancer treatment

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Colchicine binding site inhibitors (CBSIs) exhibit antitumor properties, including anti-angiogenesis and overcoming multidrug resistance.
• Current CBSIs face limitations in efficacy, toxicity, and pharmacokinetics, hindering clinical approval for cancer treatment.
• Dual-target inhibition presents a promising strategy to enhance anticancer effects and mitigate adverse events.

Purpose of the Study:

• To review dual-target inhibitors targeting the colchicine binding site (CBS).
• To summarize the design strategies employed for these dual-target inhibitors.
• To analyze the biological activities of reviewed dual-target CBS inhibitors.

Main Methods:

• Literature search for dual-target inhibitors of the colchicine binding site.
• Analysis of reported design strategies for dual-target CBS inhibitors.
• Compilation and summary of biological activity data for these inhibitors.

Main Results:

• Dual-target inhibitors offer improved anticancer efficacy compared to single-target agents.
• Specific design strategies have been identified to enhance potency and selectivity.
• These inhibitors demonstrate potential in overcoming drug resistance and reducing toxicity.

Conclusions:

• Dual-target inhibitors based on the colchicine binding site represent a viable strategy for novel cancer therapeutics.
• Further research into design and optimization can lead to clinically approved drugs.
• This review provides a foundation for developing next-generation dual inhibitors targeting the CBS.